SMT201600196B - Trattamento con porfirina di patologie neurodegenerative - Google Patents

Trattamento con porfirina di patologie neurodegenerative

Info

Publication number
SMT201600196B
SMT201600196B SM201600196T SM201600196T SMT201600196B SM T201600196 B SMT201600196 B SM T201600196B SM 201600196 T SM201600196 T SM 201600196T SM 201600196 T SM201600196 T SM 201600196T SM T201600196 B SMT201600196 B SM T201600196B
Authority
SM
San Marino
Prior art keywords
porphyrinal
treatment
neurodegenerative pathologies
pathologies
neurodegenerative
Prior art date
Application number
SM201600196T
Other languages
English (en)
Inventor
Manisha Patel
Brian Day
John Mcmanus
Original Assignee
Aeolus Sciences Inc
Nat Jewish Health
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeolus Sciences Inc, Nat Jewish Health, Univ Colorado Regents filed Critical Aeolus Sciences Inc
Publication of SMT201600196B publication Critical patent/SMT201600196B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM201600196T 2010-10-06 2016-06-23 Trattamento con porfirina di patologie neurodegenerative SMT201600196B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39027010P 2010-10-06 2010-10-06
PCT/US2011/055172 WO2012048164A2 (en) 2010-10-06 2011-10-06 Porphyrin treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
SMT201600196B true SMT201600196B (it) 2016-08-31

Family

ID=45928446

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600196T SMT201600196B (it) 2010-10-06 2016-06-23 Trattamento con porfirina di patologie neurodegenerative

Country Status (19)

Country Link
US (1) US20130225545A1 (it)
EP (1) EP2625180B1 (it)
JP (1) JP5908485B2 (it)
KR (1) KR101932149B1 (it)
AU (1) AU2011311903B2 (it)
CA (1) CA2813570A1 (it)
DK (1) DK2625180T3 (it)
ES (1) ES2574789T3 (it)
HR (1) HRP20160514T1 (it)
HU (1) HUE029083T2 (it)
IL (1) IL225624A (it)
LT (1) LT2625180T (it)
NZ (1) NZ609924A (it)
PL (1) PL2625180T3 (it)
PT (1) PT2625180E (it)
RS (1) RS54911B1 (it)
SI (1) SI2625180T1 (it)
SM (1) SMT201600196B (it)
WO (1) WO2012048164A2 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130150A2 (en) 2011-12-02 2013-09-06 The Regents Of The University Of Colorado, A Body Corporate Metalloporphyrin neurological treatments
WO2016168343A1 (en) * 2015-04-13 2016-10-20 National Jewish Health Thiocyanate salts for anti-inflammation
KR20250079633A (ko) 2023-11-27 2025-06-04 서울대학교산학협력단 체내 주입형 하이드로겔 및 그 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571908A (en) * 1987-01-02 1996-11-05 Sun Company, Inc. (R&M) Porphyrins
ES2198767T3 (es) * 1997-11-03 2004-02-01 Duke University Porfirinas sustituidas.
DE69928655T2 (de) * 1998-04-24 2006-08-24 Duke University Substituierte porphyrine
WO2000009111A2 (en) * 1998-08-11 2000-02-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibitors of amyloid formation
EP1616869B1 (en) * 1999-01-25 2012-04-04 National Jewish Health Substituted porphyrins and their therapeutic use
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
CA2528347A1 (en) * 2003-06-06 2005-01-06 Eukarion, Inc. Orally bioavailable low molecular weight metalloporphyrins as antioxidants
GB0415663D0 (en) * 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound
JP2009298731A (ja) * 2008-06-13 2009-12-24 Tokyo Metropolitan Univ 酸化傷害を抑制する金属ポルフィリン錯体、及びそれを用いた医薬組成物
US20120289492A1 (en) * 2009-09-02 2012-11-15 The Regents Of The University Of Colorado, A Body Corporate Methods of treating mitochondrial disorders using metalloporphyrins

Also Published As

Publication number Publication date
EP2625180A4 (en) 2014-05-14
NZ609924A (en) 2015-02-27
LT2625180T (lt) 2016-09-12
PL2625180T3 (pl) 2016-10-31
SI2625180T1 (sl) 2016-08-31
DK2625180T3 (en) 2016-06-06
RS54911B1 (sr) 2016-10-31
AU2011311903B2 (en) 2016-11-17
AU2011311903A1 (en) 2013-05-23
WO2012048164A2 (en) 2012-04-12
WO2012048164A3 (en) 2012-07-19
CA2813570A1 (en) 2012-04-12
EP2625180B1 (en) 2016-03-02
EP2625180A2 (en) 2013-08-14
JP2013542936A (ja) 2013-11-28
KR101932149B1 (ko) 2018-12-26
PT2625180E (pt) 2016-06-07
IL225624A0 (en) 2013-06-27
HUE029083T2 (en) 2017-02-28
IL225624A (en) 2017-11-30
JP5908485B2 (ja) 2016-05-11
KR20130115275A (ko) 2013-10-21
HRP20160514T1 (hr) 2016-09-23
US20130225545A1 (en) 2013-08-29
ES2574789T3 (es) 2016-06-22

Similar Documents

Publication Publication Date Title
IL250357A0 (en) Treatment of lupus nephritis using laquinimod
SMT201600370B (it) Complessi chelati di oligonucleotidi
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
BR112013002845A2 (pt) combinação de susbtâncias ativas
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
EP2641343A4 (en) CONFIGURATION OF A BUILDING
PT3222272T (pt) Composição farmacêutica de carbetocina
EP2599430A4 (en) Borescope
EP2572995A4 (en) TABLETS CASSETTE
HRP20181190T1 (hr) SPOJEVI KOJI SU KORISNI ZA LIJEČENJE AIDS-a
BR112014003878A2 (pt) síntese de r-bifenilalaninol
EP2801020A4 (en) MOVEMENT OF ANIMATIONS
EP2499255A4 (en) EFFICIENT PRODUCTION OF PEPTIDES
HUE040769T2 (hu) Iduronát-2-szulfatáz tisztítása
DK2552212T3 (da) Forbedret formulering
EP2694107A4 (en) TREATMENT OF DERMATOLOGICAL SUFFERING
EP2691361A4 (en) SYNTHESIS OF DIAZIDEN
SMT201600059B (it) Trattamento di infezioni da streptococco
DE112011103919A5 (de) Endoskop
EP2714694A4 (en) BAKTERIOCHLORIMIDE
EP2690717A4 (en) PLUG CLAMP
IT1398549B1 (it) Silil- derivati di polisaccaridi
SMT201600196B (it) Trattamento con porfirina di patologie neurodegenerative
EP2595966A4 (en) SYNTHESIS OF CYCLOPENTACHINAZOLINES